Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE). METHODS: An observational, nonrandomized, comparative multicenter cohort study was conducted at 17 Spanish and 1 Italian hospitals. Consecutive adult patients diagnosed of EFIE were included. Outcome measurements were death during treatment and at 3 months of follow-up, adverse events requiring treatment withdrawal, treatment failure requiring a change of antimicrobials, and relapse. RESULTS: A larger percentage of AC-treated patients (n = 159) had previous chronic renal failure than AG-treated patients (n = 87) (33% vs 16%, P = .004), and AC patients had a higher incidence of cancer (18% vs 7%, P = .015), transplantation (6% vs 0%, P = .040), and healthcare-acquired infection (59% vs 40%, P = .006). Between AC and AG-treated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P = .81) or at 3-month follow-up (8% vs 7%, P = .72), in treatment failure requiring a change in antimicrobials (1% vs 2%, P = .54), or in relapses (3% vs 4%, P = .67). However, interruption of antibiotic treatment due to adverse events was much more frequent in AG-treated patients than in those receiving AC (25% vs 1%, P < .001), mainly due to new renal failure (≥25% increase in baseline creatinine concentration; 23% vs 0%, P < .001). CONCLUSIONS: AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study by Fernández-Hidalgo et al, 191 26% of the 272 patients had high-level aminoglycoside-resistant strains of E faecalis.”
In the citing paper
“Sixth, in the larger study, there were no significant differences between ampicillin-ceftriaxone and ampicillin-gentamicin in the need for surgery, complications (except for fewer cases of renal failure in the ampicillin-ceftriaxone group), relapse, or mortality.”
In the citing paper
“Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the larger study.”
In the citing paper
“Fourth, in the larger study, the median age was 70 years in both treatment groups; however, patients in the ampicillin-ceftriaxone group were generally sicker and had more comorbid conditions (eg, chronic renal failure [P=0.004],neoplasm [P=0.015], and nosocomial acquisition of infection [P=0.006]).”
In the citing paper
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study 190 and 272 in the other study.191”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions IE was defined as definite or possible according to the modified Duke criteria [10].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey
Selton-Suty, C., Célard, M., Le Moing, V., Doco-Lecompte, T., Chirouze, C., Iung, B., Strady, C., Revest, M., Vandenesch, F., Bouvet, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis199 · Cited by 710
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525 · cited 1×
“Healthcare-associated IE [11] and catheter-related bacteremia [12] have been defined elsewhere.”
BackgroundContemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis
Fernández‐Hidalgo, N., Almirante, B., Tornos, P., Pigrau, C., Sambola, A., Igual, A., & Pahissa, A. (2008) · Clinical Infectious Diseases · doi:10.1086/592576 · Cited by 217
Self-citationGavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202 · cited 3×
“Since the publication of an observational, nonrandomized, multicenter clinical trial in 2007 [9], the ampicillin plus ceftriaxone (AC) combination has been recognized as a viable alternative for treating E.”
BackgroundSelf-citationMcDonald, J. R., Olaison, L., Anderson, D. J., Hoen, B., Miro, J. M., Eykyn, S., Abrutyn, E., Fowler, V. G., Habib, G., Selton-Suty, C., et al. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.020 · Cited by 170
Cited by
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study(190) and 272 in the other study.(191) Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the la…”
BackgroundResult2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Self-citationMechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772
“Seemingly redundant therapy, such as the combination of the b-lactams, ampicillin and ceftriaxone, has been shown clinically to be as efficacious as more traditional combinations with aminoglycosides, with the benefit of less toxicity and the ability to bypass high-level resistance to aminoglycosides [133,134].”
BackgroundThe Enterococcus: a Model of Adaptability to Its Environment
García-Solache, M., & Rice, L. B. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-18 · Cited by 754
“faecalis, and ceftriaxone, which is not (147, 148).”
BackgroundChallenges in Infective Endocarditis
Cahill, T. J., Baddour, L. M., Habib, G., Hoen, B., Salaun, E., Pettersson, G. B., Schäfers, H. J., & Prendergast, B. D. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.066 · Cited by 715
“effective as ampicillin/gentamicin, with reduced levels of nephrotoxicity (94,95).”
BackgroundThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
“faecalis, such as endocarditis or bacteremia [325,326].”
Crank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
“faecalis, ampicillin with ceftriaxone should be considered an alternative treatment option, as it has shown efficacy similar to that of ampicillin with gentamicin, but with less nephrotoxicity.(66,68) The mechanism for this bactericidal synergy is due to the saturation of different PBPs by each agent.”
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Baltimore, R. S., Gewitz, M., Baddour, L. M., Beerman, L. B., Jackson, M. A., Lockhart, P. B., Pahl, E., Schutze, G. E., Shulman, S. T., & Willoughby, R. (2015) · Circulation · doi:10.1161/cir.0000000000000298 · Cited by 398
“The combination of ampicillin plus ceftriaxone was reported to be effective for aminoglycoside nonsusceptible Enterococcus faecalis strains first in a report from Spain and recently confirmed in a multi-institutional observational report.(123,124) Enterococci are resistant to ceftriaxone and other cephalosporins, and…”
BackgroundManagement Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Beganovic, M., Luther, M. K., Rice, L. B., Arias, C. A., Rybak, M. J., & LaPlante, K. L. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy064 · Cited by 234
“Furthermore, 10 patients did not receive combination therapy after stopping gentamicin and completed their treatment course with ampicillin monotherapy [11].”
BackgroundInfluentialFaron, M. L., Ledeboer, N. A., & Buchan, B. W. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00211-16 · Cited by 227
“For patients who are aminoglycoside intolerant, combination treatment with ampicillin and ceftriaxone was observed to be as effective as ampicillin and gentamicin in treating VRE with the gentamicin HLR phenotype (24).”
BackgroundJCS 2017 Guideline on Prevention and Treatment of Infective Endocarditis
Nakatani, S., Ohara, T., Ashihara, K., Izumi, C., Iwanaga, S., Eishi, K., Okita, Y., Daimon, M., Kimura, T., Toyoda, K., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0549 · Cited by 179
Prevalence of Infective Endocarditis in Enterococcus faecalis Bacteremia
Dahl, A., Iversen, K. K., Tønder, N., Høst, N. B., Arpi, M., Dalsgaard, M., Chehri, M., Soerensen, L. L., Fanoe, S., Junge, S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.059 · Cited by 175
Native-Valve Infective Endocarditis
Chambers, H. F., & Bayer, A. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2000400 · Cited by 166
Vancomycin-Resistant Enterococci
Miller, W. R., Murray, B. E., Rice, L. B., & Arias, C. A. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.006 · Cited by 153
Endocarditis and Intravascular Infections
Fowler, V. G., Scheld, W. M., & Bayer, A. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00082-5 · Cited by 152
Smith, J. R., Barber, K. E., Raut, A., Aboutaleb, M., Sakoulas, G., & Rybak, M. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv007 · Cited by 148
Revest, M., Camou, F., Senneville, E., Caillon, J., Laurent, F. J., Calvet, B., Feugier, P., Batt, M., & Chidiac, C. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.04.014 · Cited by 124
“[122,123].”
Monticelli, J., Knezevich, A., Luzzati, R., & Bella, S. D. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.01.001 · Cited by 122
How do I manage a patient with enterococcal bacteraemia?
Turco, E. R. D., Bartoletti, M., Dahl, A., Cervera, C., & Pericàs, J. M. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.029 · Cited by 121
Goldstein, R. E. R., Micallef, S. A., Gibbs, S. G., George, A., Claye, E., Sapkota, A. R., Joseph, S. W., & Sapkota, A. R. (2013) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2013.07.039 · Cited by 121
“5%) of the enterococci isolated in this study is cause for concern given that the current international guidelines for treatment of Enterococcus infections recommend a combination of ampicillin and an aminoglycoside antibiotic (including gentamicin, streptomycin, and kanamycin) (Fernández-Hidalgo et al., 2013).”
BackgroundPericàs, J. M., Cervera, C., del Río, A., Moreno, A., de la Maria, C. G., Almela, M., Falces, C., Ninot, S. P. I., Castañeda, X., Armero, Y., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12756 · Cited by 110
“[34], who recently found similar outcomes with A+C and A+G for EFIE.”
ResultDahl, A., Rasmussen, R. V., Bundgaard, H., Hassager, C., Bruun, L. E., Lauridsen, T. K., Moser, C., Sogaard, P., Arpi, M., & Bruun, N. E. (2013) · Circulation · doi:10.1161/circulationaha.112.001170 · Cited by 108
van Duijkeren, E., Schwarz, C., Bouchard, D. S., Catry, B., Pomba, C., Baptiste, K. E., Moreno, M. Á., Rantala, M. H. J., Ružauskas, M., Sandérs, P., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz161 · Cited by 106
Yim, J., Smith, J. R., & Rybak, M. J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1922 · Cited by 100
“However, mortality up to 22% while on this antimicrobial combination and 8% at 3-month follow-up were reported, warranting investigation of alternative therapies.(9) Resistance to early-generation cephalosporins is intrinsic among enterococci, although two new agents, ceftaroline and ceftobiprole, demonstrate limited…”
BackgroundA Contemporary Picture of Enterococcal Endocarditis
Pericàs, J. M., Llopis, J., Muñoz, P., Gálvez-Acebal, J., Kestler, M., Valerio, M., Hernández-Meneses, M., Goenaga, M. Á., Cobo-Belaustegui, M., Montejo, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.047 · Cited by 99
Self-citationCombatting resistant enterococcal infections: a pharmacotherapy review
Mercuro, N. J., Davis, S. L., Zervos, M., & Herc, E. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1479397 · Cited by 98
“Interruption in antibiotic treatment due to adverse effects was more common in the aminoglycoside group, mostly from renal failure [41].”
BackgroundDilworth, T. J., Ibrahim, O. M., Hall, P. R., Sliwinski, J., Walraven, C. J., & Mercier, R.-C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-13 · Cited by 95
“(25) Our results show an unrecognized, beneficial effect of combination therapy, especially combinations often used together like piperacillin-tazobactam and VAN.”
BackgroundEpidemiología de la endocarditis infecciosa en España en los últimos 20 años
Fernández‐Hidalgo, N., & Tornos, P. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.05.003 · Cited by 94
Self-citationFarman, M., Yasir, M., Al-Hindi, R. R., Farraj, S. A., Jiman-Fatani, A. A., Alawi, M., & Azhar, E. I. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0508-4 · Cited by 93
“In particular, gentamycin is used as a synergistic antibiotic with ampicillin [31], and amoxicillin is the first choice of treatment for Fig.”
BackgroundResistance to β-lactams in enterococci
Gagetti, P. S., Bonofiglio, L., Gabarrot, G. G., Kaufman, S. C., Mollerach, M. E., Vigliarolo, L., von Specht, M., Toresani, I., & Lopardo, H. Á. (2018) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2018.01.007 · Cited by 89
Current Challenges in the Management of Infective Endocarditis
Cuervo, G., Escrihuela-Vidal, F., Gudiol, C., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641243 · Cited by 88
“When this combination cannot be used due to high-level aminoglycoside resistance or an unacceptable risk of toxicity, combination with ceftriaxone (socalled “double beta-lactam”) is recommended, which achieves bactericidal action presumably through the complementary saturation of penicillin-binding proteins (PBPs) (13…”
BackgroundLerche, C. J., Schwartz, F. A., Theut, A. M., Fosbøl, E. L., Iversen, K. K., Bundgaard, H., Høiby, N., & Moser, C. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.643335 · Cited by 86
Guidelines on Implementing Antimicrobial Stewardship Programs in Korea
Yoon, Y. K., Kwon, K. T., Jeong, S. J., Moon, C., Kim, B., Kiem, S., Kim, H.-S., Heo, E., Kim, S., Korean Society for Antimicrobial Therapy, et al. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0098 · Cited by 86
“In patients with infective endocarditis, antimicrobial combination therapy is recommended, with the drug combination depending on antimicrobial susceptibility test results [63, 64].”
Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse
Danneels, P., Hamel, J., Picard, L., Rezig, S., Martinet, P., Lorleac’h, A., Talarmin, J., Buzelé, R., Guimard, T., Moal, G. L., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac777 · Cited by 83
“This dual therapy has the disadvantage of a high risk of acute kidney injury (25% of patients) and loses its synergistic effect against isolates with high-level aminoglycoside resistance (HLAR) [10, 11].”
BackgroundResultInfluentialAminoglycosides: how should we use them in the 21st century?
Jackson, J., Chen, C., & Buising, K. L. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000012 · Cited by 84
Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
Hidalgo, L. H., Fernández-Rubio, B., Márquez, R. L., López-Cortés, L. E., Gil-Navarro, M. V., & de Alarcón, A. (2023) · Antibiotics · doi:10.3390/antibiotics12040704 · Cited by 81
Enterococcus faecalisinfective endocarditis: focus on clinical aspects
Dahl, A., & Bruun, N. E. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.832482 · Cited by 80
Epidemiology of Infective Endocarditis in Spain in the Last 20 Years
Fernández‐Hidalgo, N., & Tornos, P. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.05.002 · Cited by 79
Self-citationDahl, A., Lauridsen, T. K., Arpi, M., Sorensen, L. L., Østergaard, C., Søgaard, P., & Bruun, N. E. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw383 · Cited by 79
Kumar, P., Chauhan, V., Silva, J. R. A., Lameira, J., d’Andrea, F. B., Li, S.-G., Ginell, S. L., Freundlich, J. S., Alves, C. N., Bailey, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00866-17 · Cited by 78
“tuberculosis and Enterococcus faecalis was recently observed by two different groups (24, 25).”
BackgroundSparo, M. D., Delpech, G., & Allende, N. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03073 · Cited by 78
Aminoglycosides for infective endocarditis: time to say goodbye?
Lebeaux, D., Fernández‐Hidalgo, N., Pilmis, B., Tattevin, P., & Mainardi, J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.017 · Cited by 74
Self-citationManaging infective endocarditis in the elderly: new issues for an old disease
Forestier, E., Fraisse, T., Baudron, C. R., Selton‐Suty, C., & Pagani, L. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s101902 · Cited by 73
Infective Endocarditis in High-Income Countries
Nappi, F., Martuscelli, G., Bellomo, F., Singh, S. S. A., & Moon, M. R. (2022) · Metabolites · doi:10.3390/metabo12080682 · Cited by 71
Klein, M., & Wang, A. (2014) · Journal of Intensive Care Medicine · doi:10.1177/0885066614554906 · Cited by 68
“Multidisciplinary care teams consisting of infectious disease, cardiology, and cardiac surgery physicians that apply professional society guidelines have been shown to decrease renal failure, multisystem organ failure, death from embolic events, and overall mortality.(48) The effect of this strategy was likely due to…”
Rice, L. B., Desbonnet, C. R., Tait-Kamradt, A. G., Garcia-Solache, M. A., Lonks, J. R., Moon, T. M., D'Andréa, É. D., Page, R., & Peti, W. (2018) · mBio · doi:10.1128/mbio.00361-18 · Cited by 66
“faecalis native valve endocarditis (5, 6).”
Infective endocarditis: trends, surgical outcomes, and controversies
Jamil, M., Sultan, I. S., Gleason, T. G., Navid, F., Fallert, M., Suffoletto, M. S., & Kilic, A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.45 · Cited by 64
“Ceftriaxone alone for Streptococcal IE and ceftriaxone plus ampicillin for Enterococcal IE are adequate treatments (19,22,23).”
BackgroundSmith, J. R., Barber, K. E., Raut, A., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-15 · Cited by 62
“CRO and AMP together are active against PBPs 1 to 5, and recent clinical data describing the effective use of this combination further establish this possibility (43).”
BackgroundEnterococcal Endocarditis Revisited
Pericàs, J. M., Zboromyrska, Y., Cervera, C., Castañeda, X., Almela, M., García-de-la-Mària, C., Mestres, C. A., Falces, C., Quintana, E., Ninot, S. P. I., et al. (2015) · Future Microbiology · doi:10.2217/fmb.15.46 · Cited by 60
Sakoulas, G., Olson, J., Yim, J., Singh, N. B., Kumaraswamy, M., Quach, D., Rybak, M. J., Pogliano, J., & Nizet, V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01192-16 · Cited by 60
“Recently, combination ampicillin-plus-ceftriaxone beta-lactam therapy has been employed in the treatment of Enterococcus faecalis endocarditis in order to avoid aminoglycoside therapy (34).”
MethodWhat’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Hamiwe, T., Kock, M. M., Magwira, C. A., Antiabong, J. F., & Ehlers, M. M. (2018) · Environmental Pollution · doi:10.1016/j.envpol.2018.11.040 · Cited by 59
Story‐Roller, E., Maggioncalda, E. C., & Lamichhane, G. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00614-19 · Cited by 59
Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy
Patel, R., & Gallagher, J. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556879 · Cited by 58
“A large multicenter, observational trial comparing ampicillin plus ceftriaxone versus ampicillin plus gentamicin demonstrated similar mortality in both groups despite the fact that patients in the ampicillin and ceftriaxone group had more significant comorbidities.(45) However, discontinuation of the drug for reasons…”
BackgroundResultSingh, K. V., Rosa, S. L. L., Somarajan, S. R., Roh, J. H., & Murray, B. E. (2015) · Infection and Immunity · doi:10.1128/iai.00884-15 · Cited by 56
“, aminoglycosides, although more recent use of ampicillin in combination with ceftriaxone seems to have alleviated this concern (7).”
BackgroundThieme, L., Klinger-Strobel, M., Hartung, A., Stein, C., Makarewicz, O., & Pletz, M. W. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky051 · Cited by 55
Infective endocarditis in children: an update
Dixon, G. L. J., & Christov, G. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000370 · Cited by 53
Enterococcus Faecalis Endocarditis: What’s Next?
Fernández‐Hidalgo, N., Escolà‐Vergé, L., & Pericàs, J. M. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0247 · Cited by 52
Self-citationInfectious endocarditis: An update for emergency clinicians
Long, B., & Koyfman, A. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.06.074 · Cited by 51
“Though aminoglycosides were recommended in the past, especially with enterococcal infection, there is increased patient harm with aminoglycosides including increased renal injury, with no benefit to clearing infection [80-83].”
BackgroundRafei, A. E., DeSimone, D. C., Narichania, A. D., Sohail, M. R., Vikram, H. R., Li, Z., Steckelberg, J. M., Wilson, W. R., & Baddour, L. M. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.06.013 · Cited by 50
Novel Strategies for the Management of Vancomycin-Resistant Enterococcal Infections
Contreras, G., Munita, J. M., & Arias, C. A. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0680-y · Cited by 50
Aloy, B., Launay‐Vacher, V., Bleibtreu, A., Bortolotti, P., Faure, E., Filali, A., Gauzit, R., Gilbert, M., Lesprit, P., Mahieu, R., et al. (2019) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2019.06.010 · Cited by 50
Bartash, R. M., & Nori, P. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.07.019 · Cited by 49
Miro, J. M., Pericas, J. M., & del Rio, A. (2013) · Circulation · doi:10.1161/circulationaha.113.002431 · Cited by 46
Aminoglycoside-Induced Nephrotoxicity—A Focus on Monitoring: A review of Literature
Destache, C. J. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014546102 · Cited by 44
“However, a prospective, randomized trial for patients with enterococcal endocarditis compared ampicillin þ ceftriaxone (A þ C) to ampicillin þ gentamicin (A þ G).(45) This trial was conducted at 17 Spanish hospitals and 1 Italian hospital from 2005 to 2011.”
MethodAntibiotic interactions shape short-term evolution of resistance in E. faecalis
Dean, Z., Maltas, J., & Wood, K. B. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008278 · Cited by 43
“Dual β-lactam combinations like CRO-AMP have been particularly effective in treatment of endocarditis infections in the clinical setting (44, 40).”
BackgroundA review of current treatment strategies for infective endocarditis
Paz, D. L., Lakbar, I., & Tattevin, P. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1822165 · Cited by 43
Escolà‐Vergé, L., Fernández‐Hidalgo, N., Larrosa, N., Fernandez-Galera, R., & Almirante, B. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04117-x · Cited by 44
Self-citationFalcone, M., Russo, A., & Venditti, M. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.012 · Cited by 41
Self-citationPericàs, J. M., Cervera, C., Moreno, A., García-de-la-Mària, C., Almela, M., Falces, C., Quintana, E., Vidal, B., Llopis, J., Fuster, D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192387 · Cited by 41
Linezolid-resistant staphylococcal bacteraemia: A multicentre case–case–control study in Italy
Russo, A., Campanile, F., Falcone, M., Tascini, C., Bassetti, M., Goldoni, P., Trancassini, M., Siega, P. D., Menichetti, F., Stefani, S., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.008 · Cited by 40
Self-citationEnterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species
Arias, C. A., & Murray, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00202-2 · Cited by 40
Pericàs, J. M., Ambrosioni, J., Muñóz, P., de Alarcón, A., Kestler, M., Marí-Hualde, A., Moreno, A., Goenaga, M. Á., Fariñas, M. C., Rodríguez, R., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.056 · Cited by 39
Self-citationInfective Endocarditis in the Elderly: Challenges and Strategies
Serrano, C. B., Vela, S., García‐Blas, S., Pérez-Rivera, J.-Á., Díez‐Villanueva, P., de Gracia-León, A. I., Fuertes, E., Oltra, M. R., Ferrer, A., Belmonte-Domingo, A., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9060192 · Cited by 39
Jiao, Y., Moyá, B., Chen, M., Zavascki, A. P., Tsai, H.-Y., Tao, X., Sutaria, D. S., Louie, A., Boyce, J. D., Lucas, D. D., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-19 · Cited by 38
“Interestingly, our results also agreed with a recent clinical trial on DBL (ampicillin plus ceftriaxone) compared with ampicillin plus gentamicin against an important Gram-positive pathogen, Enterococcus faecalis (44).”
ResultAmpicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis: A Literature Review
Marıno, A., Munafò, A., Zagami, A., Ceccarelli, M., Mauro, R. D., Cantarella, G., Bernardini, R., Nunnari, G., & Cacopardo, B. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194594 · Cited by 37
A comparison of different antibiotic regimens for the treatment of infective endocarditis
Martí-Carvajal, A. J., Dayer, M., Conterno, L. D. O., Garay, A. G. G., Martí-Amarista, C. E., & Simancas‐Racines, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009880.pub2 · Cited by 35
Critical Questions About Left-Sided Infective Endocarditis
Román, J. A. S., Vilacosta, I., López, J., & Sarriá, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.016 · Cited by 35
Self-citationNakaharai, K., Sakamoto, Y., Yaita, K., Yoshimura, Y., Igarashi, S., & Tachikawa, N. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2064-7 · Cited by 35
“6 %), with no reference to liver injury [16].”
Thieme, L., Hartung, A., Makarewicz, O., & Pletz, M. W. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa129 · Cited by 34
Infective Endocarditis by Lactobacillus Species—A Narrative Review
Ιωάννου, Π., Ziogou, A., Giannakodimos, I., Giannakodimos, A., Baliou, S., & Samonis, G. (2024) · Antibiotics · doi:10.3390/antibiotics13010053 · Cited by 34
Pericàs, J. M., Cervera, C., Moreno, A., García-de-la-Mària, C., Almela, M., Falces, C., Quintana, E., Vidal, B., Llopis, J., Fuster, D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196317 · Cited by 34
Kumaraswamy, M., Do, C., Sakoulas, G., Nonejuie, P., Tseng, G.-W., King, H., Fierer, J., Pogliano, J., & Nizet, V. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.032 · Cited by 33
“Susceptibility and synergy testing was also performed on Please cite this article in press as: Monika Kumaraswamy, et al., Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies, International Journal of Antimicrobial Agents (2018),…”
BackgroundInfluentialEscolà‐Vergé, L., Peghin, M., Givone, F., Pérez-Rodríguez, M. T., Suárez-Varela, M., Meije, Y., Abelenda-Alonso, G., Almirante, B., & Fernández‐Hidalgo, N. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.07.016 · Cited by 33
Self-citationState-of-the-Art Review: Persistent Enterococcal Bacteremia
Rogers, R., & Rice, L. B. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad612 · Cited by 32
Hidalgo, L. H., de Alarcón, A., López-Cortés, L. E., Márquez, R. L., López-Cortés, L. E., Gutiérrez‐Valencia, A., & Gil-Navarro, M. V. (2020) · Antibiotics · doi:10.3390/antibiotics9100657 · Cited by 32
“[31] analyzed a large cohort of patients treated with ampicillin plus gentamycin for 4–6 weeks, in which the overall mortality after a median follow-up of 11 months was 25% and the side effects reported were 44%.”
BackgroundMethodInfluentialNative Infective Endocarditis: A State-of-the-Art-Review
Nappi, F. (2024) · Microorganisms · doi:10.3390/microorganisms12071481 · Cited by 31
“Observation data indicates that a six-week treatment regimen of ampicillin and ceftriaxone represents a viable alternative to treat infectious endocarditis caused by ampicillin-susceptible strains of E. faecalis , particularly in the absence of contraindications [19,20,42,49,60].”
Luther, M. K., Rice, L. B., & LaPlante, K. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03126-15 · Cited by 31
Escolà‐Vergé, L., Peghin, M., Givone, F., Pérez-Rodríguez, M. T., Suárez-Varela, M., Meije, Y., Abelenda-Alonso, G., Almirante, B., & Fernández‐Hidalgo, N. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.07.007 · Cited by 31
“Symptom duration, d 32 [9-38] 17 [6-48] .”
Self-citationKumar, G., Galanis, C., Batchelder, H. R., Townsend, C. A., & Lamichhane, G. (2022) · mSphere · doi:10.1128/msphere.00039-22 · Cited by 30
Watkins, R., & Bonomo, R. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00140-4 · Cited by 30
Calderón‐Parra, J., de Santiago, A. D., & Díaz, A. C. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.02.020 · Cited by 29
Ritchie, B. M., Hirning, B. A., Stevens, C. A., Cohen, S. A., & DeGrado, J. R. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1296916 · Cited by 29
Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis
Gil-Navarro, M.-V., López-Cortés, L. E., Márquez, R. L., Gálvez-Acebal, J., & de Alarcón-González, A. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12635 · Cited by 28
Enterococcus faecalis Bacteremia
Fernández‐Hidalgo, N., & Escolà‐Vergé, L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.526 · Cited by 28
Self-citationBārzdiņa, A., Plotniece, A., Sobolev, A., Pajuste, K., Bandere, D., & Brangule, A. (2024) · Antibiotics · doi:10.3390/antibiotics13040305 · Cited by 29
Biomimetic sharkskin surfaces with antibacterial, cytocompatible, and drug delivery properties
Rostami, S., Tekkeşin, A. İ., Ercan, U. K., & Garipcan, B. (2021) · Biomaterials Advances · doi:10.1016/j.msec.2021.112565 · Cited by 26
Metadata
- Authors
- Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., Gurgui, M., Peña, C., de Alarcón, A., Ruiz, J., Vilacosta, I., Montejo, M., Vallejo, N., López-Medrano, F., Plata, A., López, J., Hidalgo-Tenorio, C., Gálvez, J., Sáez, C., Lomas, J. M., Falcone, M., de la Torre, J., Martínez-Lacasa, X., & Pahissa, A.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Clínico San Carlos (ES)
- Hospital de Cruces (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Juan Ramón Jiménez (ES)
- Policlinico Umberto I (IT)
- University Hospital Mútua de Terrassa (ES)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 56
- Issue
- 9
- Pages
- 1261-1268
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137285136
- Semantic Scholar
- 9646599067b0e52124c95b08e69a38b3bd9e8a91
- Cited by
- 311
- References
- 22
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 16 · 2021: 19 · 2020: 26 · 2019: 35 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 16 · 2013: 19
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- Enterococcus faecalis, infective endocarditis, ampicillin, ceftriaxone, gentamicin, combination antibiotic therapy, aminoglycoside resistance, renal failure, treatment failure, relapse, mortality, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Ampicillin, Anti-Bacterial Agents, Ceftriaxone, Drug Therapy, Combination, Endocarditis, Female, Gentamicins, Hospitals, Humans, Italy, Male, Middle Aged, Spain, Enterococcus faecalis, Cohort Studies, Treatment Outcome, Gram-Positive Bacterial Infections, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.